Molecular Pathology

Molecular pathology is the branch of pathology that reads disease at the level of molecules — DNA, RNA, and protein — rather than at the level of organs, tissues, or whole cells.

11 frameworks, from 1858 to today · Pathology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Molecular pathology is the branch of pathology that reads disease at the level of molecules — DNA, RNA, and protein — rather than at the level of organs, tissues, or whole cells. Its practitioners ask what is happening inside a cell's genetic and biochemical machinery that explains why a disease arises, how it will behave, and which treatment might work1. The stakes are practical: a molecular test can decide whether a lung cancer patient receives a targeted drug, whether a newborn's illness has a treatable metabolic cause, or whether a tumor has been fully removed. The field is young by the standards of medicine, but it descends from older traditions of looking inside the body, and its history is a story of tools arriving and then being turned on clinical problems.

From Humors to Cells: The Prehistory of Looking Inside

For most of Western medical history, disease was explained by humoral theory — an imbalance of four bodily fluids — and diagnosis rested on the patient's outward signs. The decisive break came with the cellular pathology of Rudolf Virchow, who in the mid-nineteenth century argued that disease is located in cells, not in fluids or organs as wholes. His Cellular Pathology (1858) and his famous dictum that every cell arises from a pre-existing cell (omnis cellula e cellula) gave pathology its first modern object of study2. Virchow's program was morphological: pathologists examined tissue architecture under the microscope and classified disease by what they saw. That approach dominated for a century and remains the foundation of histopathology, but it could not explain why cells behaved abnormally — only that they did.

Chemistry Enters the Clinic

A parallel tradition developed in the clinical laboratory. Clinical chemistry — the measurement of substances in blood, urine, and other fluids — grew through the nineteenth and twentieth centuries as physicians learned to quantify glucose, urea, electrolytes, and later enzymes and hormones. These measurements gave pathology a biochemical dimension: disease could be detected by a chemical abnormality before any structural change was visible. By the mid-twentieth century, hospital laboratories routinely ran panels of such tests, and the discipline of clinical pathology had become a distinct profession alongside anatomical pathology. The two traditions — looking at tissue and measuring molecules — would eventually converge, but for decades they ran on separate tracks.

The Molecular Biology Toolkit

The intellectual foundation of molecular pathology was laid by molecular biology in the mid-twentieth century. The discovery of the double-helix structure of DNA by James Watson and Francis Crick in 1953, the elucidation of the genetic code in the 1960s, and the development of recombinant DNA techniques in the 1970s gave scientists the means to manipulate and read genetic material. Two techniques were especially consequential for pathology. The first was nucleic acid hybridization — the ability of a labeled DNA or RNA probe to find and bind its complementary sequence — which allowed specific genes to be detected in cells and tissues3. The second was the polymerase chain reaction (PCR), invented by Kary Mullis in the mid-1980s, which could amplify a tiny amount of DNA into millions of copies4. PCR turned molecular detection from a research luxury into a practical diagnostic tool, because it could find a few pathogen genomes or mutant alleles in a clinical sample.

Reading Proteins in Tissue: Immunohistochemistry

While nucleic acid methods were being developed, a parallel revolution came from antibodies. Immunohistochemistry (IHC) uses antibodies tagged with a visible marker to detect specific proteins in tissue sections, preserving the anatomical context that molecular methods often lose5. The technique grew from the work of Albert Coons and colleagues in the 1940s, who first showed that antibodies could be labeled with fluorescent dyes and used to locate antigens in tissue5. The development of enzyme-linked detection systems and, later, antigen-retrieval methods for formalin-fixed tissue made IHC a routine tool in diagnostic pathology by the 1980s and 1990s. It gave pathologists a way to identify cell types, detect infectious organisms, and — crucially — assess the presence of proteins that predict response to therapy, such as hormone receptors in breast cancer and, later, HER2.

Amplifying the Signal: Nucleic Acid Amplification Diagnostics

PCR and its descendants — real-time PCR, transcription-mediated amplification, and others — became the backbone of molecular diagnostics for infectious disease. The ability to detect and quantify pathogen nucleic acid changed the management of infections such as HIV, hepatitis B and C, and tuberculosis, where viral load or bacterial burden guides treatment. The COVID-19 pandemic of 2020 made nucleic acid amplification a household phrase, but the technology had been central to clinical microbiology for decades before. These methods also introduced a new kind of laboratory workflow: extraction of nucleic acid from a specimen, amplification, and detection — a sequence that required dedicated facilities and strict contamination control, because the technique's sensitivity made it vulnerable to false positives from stray DNA.

Molecular Genetic Testing and the Germline

The 1980s and 1990s brought the first clinical genetic tests for inherited disease. The discovery of the gene responsible for Huntington's disease in 1993 and the cloning of the cystic fibrosis gene in 1989 are landmarks: they showed that a specific mutation could be identified in a patient's DNA and used for diagnosis, carrier detection, and prenatal testing. Sanger sequencing, developed in the late 1970s, was the workhorse for reading individual genes6. Molecular genetic testing moved from research laboratories into clinical genetics and, increasingly, into pathology departments, which took on the task of extracting and analyzing DNA from patient samples. The distinction between germline mutations (inherited, present in every cell) and somatic mutations (acquired, present only in the tumor or affected tissue) became a central organizing concept.

Cancer as a Molecular Disease: Targeted Therapy

The idea that cancer is driven by specific genetic alterations — activated oncogenes and inactivated tumor suppressors — emerged from research in the 1970s and 1980s. The clinical payoff came with targeted therapies7. Imatinib, approved in 2001 for chronic myeloid leukemia, was the paradigm: it inhibits the BCR-ABL fusion protein produced by a chromosomal translocation, and its success depended on detecting that translocation in the patient's tumor. The same logic spread to solid tumors: EGFR mutations in lung cancer, BRAF mutations in melanoma, and HER2 amplification in breast cancer each became a biomarker that determined whether a targeted drug should be used. Molecular pathology thus became not only diagnostic but predictive — its tests guided therapy selection7. This shift required pathologists to work closely with oncologists and to develop validated assays for formalin-fixed, paraffin-embedded tissue, the standard material of surgical pathology.

Genomic Pathology: From Single Genes to Whole Genomes

The completion of the Human Genome Project in 2003 and the subsequent collapse in sequencing costs transformed the field again. Next-generation sequencing (NGS) allowed many genes — or the whole exome or genome — to be read in a single assay8. In pathology, this made possible tumor profiling panels that assess dozens or hundreds of cancer-associated genes at once, and it opened the door to detecting inherited disease across broad gene sets. Genomic pathology is the application of these high-throughput methods to clinical tissue and blood samples. It brought new challenges: the interpretation of variants of uncertain significance, the need for bioinformatics pipelines, and the integration of genomic data into pathology reports. The pathologist's role expanded from describing morphology to interpreting complex molecular data.

Liquid Biopsy: Sampling the Blood

A more recent development is the detection of tumor-derived material — circulating tumor DNA, circulating tumor cells, and other markers — in blood and other body fluids9. The concept that a tumor sheds DNA into the circulation was established in research by the early 2000s, and by the 2010s liquid biopsy assays were entering clinical use for monitoring treatment response, detecting resistance mutations, and, in some settings, screening for cancer. Liquid biopsy offers what tissue biopsy cannot: a minimally invasive, repeatable sample that can be taken over time9. Its limitations — low amounts of tumor DNA in early disease, and the need for highly sensitive assays — remain active areas of development.

Single-Cell Molecular Analysis

The most recent frontier is the analysis of individual cells10. Traditional molecular methods grind up a tissue sample and measure the average of thousands of cells, losing the distinction between, say, a tumor cell and an immune cell10. Single-cell sequencing, which became practical in the 2010s, isolates and sequences the RNA or DNA of individual cells, revealing the heterogeneity of tumors and the diversity of cell types in a tissue. In pathology, this approach is still largely research-oriented, but it promises to refine diagnosis and to explain why some tumors resist therapy. It represents the logical endpoint of the field's long movement toward finer resolution: from organ to tissue to cell to molecule to the single cell's own transcriptome.

The Present: Integration and Open Questions

Today molecular pathology is woven into the daily work of diagnostic laboratories. Immunohistochemistry remains the first-line tool for many protein biomarkers; PCR and NGS handle nucleic acid analysis; and genomic panels guide therapy in oncology. The field's history is one of convergence — the morphological tradition of cellular pathology and the quantitative tradition of clinical chemistry met in the molecular laboratory, and the pathologist now reads both tissue and data. Open questions remain: how to interpret variants of uncertain significance, how to make genomic testing equitable and affordable, how to validate liquid biopsy for early detection, and how to integrate single-cell and spatial methods into routine diagnosis. The direction of travel is clear — toward more data, finer resolution, and closer coupling of molecular findings to treatment decisions — but the field is still working out how to use that power responsibly.

References

  1. Molecular pathology, Wikipedia
  2. Rudolf Virchow, Wikipedia
  3. In situ hybridization, Wikipedia
  4. Polymerase chain reaction, Wikipedia
  5. Immunohistochemistry, Wikipedia
  6. Sanger sequencing, Wikipedia
  7. Targeted therapy, Wikipedia
  8. Massively parallel sequencing, Wikipedia
  9. Liquid biopsy, Wikipedia
  10. Single-cell analysis, Wikipedia

The frameworks of Molecular Pathology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1858-Present
  2. 1900-Present
  3. 1940-Present
  4. 1960-2000
  5. 1970-1995
  6. 1985-Present
  7. 1985-Present
  8. 2001-Present
  9. 2005-Present
  10. 2010-Present
  11. 2015-Present
A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Molecular Pathology is a planet in Nousfarer

Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.

Land on Molecular Pathology

Related fields

More in Pathology

See where Molecular Pathology sits on the Map of Human Knowledge